Briefly, targeting the NLRP3 inflammasome signaling pathway represents a promising therapeutic strategy for RA and its comorbidities, and ongoing research would facilitate the development of novel and effective treatments for this disease. This evidence concerns the gene NLRP3 and rheumatoid arthritis.